The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations

Journal of General Internal Medicine

Volumn 24, Issue 4, 2009, Pages 457-463

  Au, David H ^a,b   Bryson, Christopher L ^a,b   Chien, Jason W ^b,c   Sun, Haili ^a   Udris, Edmunds M ^a   Evans, Laura E ^d   Bradley, Katharine A ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Smoking cessation

Indexed keywords

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; SMOKING CESSATION; TIME;

AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING CESSATION; TIME FACTORS;

EID: 67649958168     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-009-0907-y     Document Type: Article

References (37)

1. Data Fact Sheet: Chronic Obstructive Pulmonary Disease, National Heart Blood and Lung Institiute. NIH Publication Number 2003;30-5229.
2. Calverley PM. Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1:121-4.
3. Kanner RE, Connett JE, Williams DE, Buist AS. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med. 1999;106:410-6. (Pubitemid 29190593)
4. Bolliger CT, Zellweger JP, Danielsson T, et al. Influence of long-term smoking reduction on health risk markers and quality of life. Nicotine Tob Res. 2002;4:433-9. (Pubitemid 35469977)
5. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233-9. (Pubitemid 40216240)
6. Faulkner MA, Lenz TL, Stading JA. Cost-effectiveness of smoking cessation and the implications for COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:279-87.
7. Hoogendoorn M, Welsing P, Rutten-van Molken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin. 2008;24:51-61. (Pubitemid 351160238)
8. Johansson PM, Tillgren PE, Guldbrandsson KA, Lindholm LA. A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children. Scand J Public Health. 2005;33:343-52. (Pubitemid 41582345)
9. Tsevat J. Impact and cost-effectiveness of smoking interventions. Am J Med. 1992;93:43S-7S.
10. Fan VS, Au D, Heagerty P, Deyo RA, McDonell MB, Fihn SD. Validation of case-mix measures derived from self-reports of diagnoses and health. J Clin Epidemiol. 2002;55:371-80. (Pubitemid 34245364)
11. The Health Consequences of Smoking: a Report of the Surgeon General. Washington DC: Department of Health and Human Services, Centers for Disease Control and Prevention. 2004;42-61.
12. Cigarette Smoking Among Adults-United States. 2003 doi:10.1001/jama.294. 2.172. JAMA 2005;294:172-3.
13. Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet. 2007;370:2044-53. (Pubitemid 50007973)
14. Ait-Khaled N, Enarson D, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ. 2001;79:971-9. (Pubitemid 33027177)
15. Fagerstrom K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs. 2002;62(Suppl 2):1-9. (Pubitemid 34809710)
16. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. Jama. 1994;272:1497-505.
17. Anthonisen NR. Long-term oxygen therapy. Ann Intern Med. 1983;99:519-27. (Pubitemid 13009219)
18. American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD [Internet]. New York: American Thoracic Society.
19. Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med. 2002;166:105-10. (Pubitemid 34693971)
20. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:822-6.
21. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:250-5. (Pubitemid 46203128)
22. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114-20. (Pubitemid 30245950)
23. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128:1995-2004. (Pubitemid 41507533)
24. Mercer PF, Shute JK, Bhowmik A, Donaldson GC, Wedzicha JA, Warner JA. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res. 2005;6:151.
25. Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med. 2007;147:639-53. (Pubitemid 351664485)
26. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645-53. (Pubitemid 38787999)
27. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J. 2005;26:835-45. (Pubitemid 41632040)
28. Cummings KM, Giovino G, Jaen CR, Emrich LJ. Reports of smoking withdrawal symptoms over a 21 day period of abstinence. Addict Behav. 1985;10:373-81. (Pubitemid 16174447)
29. Bluman LG, Mosca L, Newman N, Simon DG. Preoperative smoking habits and postoperative pulmonary complications. Chest. 1998;113:883-9. (Pubitemid 28216427)
30. Yamashita S, Yamaguchi H, Sakaguchi M, Yamamoto S, Aoki K, Shiga Y, Hisajima Y. Effect of smoking on intraoperative sputum and postoperative pulmonary complication in minor surgical patients. Respir Med. 2004;98:760-6. (Pubitemid 38842779)
31. Verra F, Escudier E, Lebargy F, Bernaudin JF, De Cremoux H, Bignon J. Ciliary abnormalities in bronchial epithelium of smokers, ex-smokers, and nonsmokers. Am J Respir Crit Care Med. 1995;151:630-4.
32. Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest. 2007;131:20-8. (Pubitemid 46122970)
33. Wilt TJ, Niewoehner D, Kane RL, MacDonald R, Joseph AM. Spirometry as a motivational tool to improve smoking cessation rates: a systematic review of the literature. Nicotine Tob Res. 2007;9:21-32. (Pubitemid 47009041)
34. Boyd NR, Windsor RA, Perkins LL, Lowe JB. Quality of measurement of smoking status by self-report and saliva cotinine among pregnant women. Matern Child Health J. 1998;2:77-83.
35. Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-xanalysis. Tob Control. 2006;15:280-5. (Pubitemid 44187513)
36. Stxate Medicaid coverage for tobacco-dependence treatments-United States. 2005. MMWR Morb Mortal Wkly Rep. 2006;55:1194-7.
37. Curry SJ, Keller PA, Orleans CT, Fiore MC. The Role of Health Care Systems in Increased Tobacco Cessation. Annu Rev Public Health 2008.